PCN112 Characteristics of Cancer Patients Who Seek Cytostatic Therapy in Korea: A Pilot Study  by Kim, E.H. et al.
n66), 121 for Everolimus (E; n468), 143 for Sunitinib (Su; n1520) and 192 for
BevacizumabInterferon (B, n171). Approximately one quarter of patients were
lost in the second month of treatment (T39%; So36%, P35%; E28%; Su25%;
B21%). CONCLUSIONS: Persistence in first line treatment of mRCC is very low.
Best persistence can be observed for BevacizumabInterferon which is the only
intravenous treatment in this indication. Further research may be required to eval-
uate if the increased use of oral treatments has a negative impact on patient ad-
herence and if adequate measures are required to improve this situation.
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OBJECTIVES: Although ovarian cancer has been widely studied, there is very little
documentation of patient reported outcomes (PRO) for patients with platinum-
sensitive ovarian cancer (PSOC). Initial therapy for ovarian cancer typically consists
of surgery followed by platinum-based chemotherapy. Patients are considered
platinum-sensitive if disease recurrence occurs more than 6 months after comple-
tion of platinum-based treatment. The objective of this literature review was to
obtain a clear picture of patient reported outcomes (PROs) including health related
quality of life (HRQoL), patient preferences, and health status utility for patients
with PSOC. METHODS: A systematic literature review of the peer-reviewed litera-
ture was conducted in Medline and Embase using the Cochrane approach. Studies
reporting and analyzing PROs, HRQoL, patient preferences, and health status utility
in patients with PSOC over the past 10 years were identified. RESULTS: The review
identified 19 studies reporting PROs for PSOC patients, of which 9 were PSOC only,
7 were a combination of platinum-sensitive and resistant patients and 3 were
platinum-treated recurrent patients. Of these 19 studies, there was a wide varia-
tion, with limited commonality, on the types of treatment regimens reported. In
general, QoL did not differ between therapies for PSOC patients. However, in one
study when docetaxel and carboplatin were given sequentially vs. in combination,
an improvement in QoL was demonstrated. Another study showed that statisti-
cally significant higher QoL scores were found in pegylated liposomal doxorubicin
treated patients than in gemcitabine patients. CONCLUSIONS: Given the limited
number of PSOC references and variations in treatment regimens, it was difficult to
identify common themes in patient preferences and PROs for this patient popula-
tion. PSOC patients’ preferences and perceptions of treatment are important; how-
ever, this information is missing in the evidence base. Further research is needed to
identify treatment options which improve QoL and add value to PSOC patients’
treatment experience.
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OBJECTIVES: Chronic Myeloid Leukemia (CML) is a hematologic, mostly fatal can-
cer. With the introduction of the targeted therapy imatinib, life expectancy for
these patients dramatically increased (Garcia-Manero, 2003, Deininger, 2008).
Therefore, the assessment of quality of life (QoL) is increasingly important to CML
patients taking a lifelong medication. The aim of our cross-sectional pilot study
was to assess CML patient QoL using the Euro Quality of Life-5 Dimensions (EQ-5D)
and derive utility values for each patient. METHODS: Patients with CML in Inns-
bruck, Austria completed the EQ-5D either on a tablet PC or via postal survey.
According to the ethic committee vote, inclusion criteria were: prior diagnosis of
CML, fluency in the German language, age between 18 and 80 years, and expected
survival time of at least three months. The analysis included descriptive statistics
of the sample and derivation of a utility value for each patient. RESULTS:Out of the
47 questionnaires that were sent out via mail, 31 were returned. An additional 4
patients filled out the EQ-5D using a tablet PC. Nine patients were excluded due to
lack of clinical data and/or failure to complete the questionnaire. Of the 26 patients
in the final sample, 21 patients (81%) were in the chronic phase of disease and five
(19%) had undergone allogeneic stem cell transplantation (SCT). Patients who had
undergone a SCT had a median utility of 0.701 (range 0.197-1.0); patients in the
chronic phase had a median utility of 0.887 (range 0.262-1.0).The difference be-
tween these two groups was not statistically significant (p0.345). CONCLUSIONS:
Due to limited sample size, our results should be interpreted with caution. It is
important for clinicians and health policy decision makers to consider mortality
reduction, but also consider the patients’ QoL and patient preferences in a stan-
dardized and systematic way to optimize patient care.
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OBJECTIVES: To identify differences in health-related quality of life (HRQL) be-
tween 2 consecutive Dana Farber Cancer Institute (DFCI) protocols to treat acute
lymphoblastic leukemia (ALL) diagnosed during childhood. METHODS: Children
diagnosed with standard and high risk ALL and treated according to DFCI protocol
95-001 or 00-001 at 5 and 9 Centres, respectively, in Canada and the USA were
eligible for study. Parents of patients completed Health Utilities Index (HUI) ques-
tionnaire assessments during each of 4 major phases of therapy (induction of
remission, central nervous system-directed treatment, intensification, continua-
tion), and at 2 years post-treatment. Differences between protocols in mean HRQL
scores for each phase were assessed using a t-test for independent groups. Quality-
adjusted life years (QALYs), based on mean HRQL scores for and duration of each
protocol phase, were used to determine the importance of differences. RESULTS:A
total of 381 (00-001) and 375 (95-001) patients were assessed. There were no differ-
ences between protocols in the distribution of patients by gender (p0.66) or risk
group (p0.56). During the first phase of treatment, the mean HRQL score of 00-01
patients (0.75) was importantly better (diff0.18, p0.03) than 95-001 patients
(0.67). Differences during this phase were in the attributes of dexterity (p0.03) and
emotion (p0.009). There were no significant differences (p0.05) between groups
during any of the other phases or post-treatment. Over the 5 year period, 00-001
patients experienced 0.06 greater QALYs, or 3 quality-adjusted life weeks (QALW),
than 95-001 patients. CONCLUSIONS: Assuming similar or reduced relapse and
mortality rates, 3 QALW represents an important gain in HRQL for the more recent
DFCI 00-01 protocol.
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OBJECTIVES: The benefit of adjuvant chemotherapy for early-stage breast cancer
(BrCa) patients depends on baseline recurrence risk. Gene expression profiling
(GEP) of tumours informs baseline risk prediction, potentially reducing unneces-
sary treatment and health care costs. Limited evidence exists on its clinical utility;
we explored patients’ and oncologists’ perspectives on GEP in chemotherapy
decisions. METHODS: We conducted individual interviews with medical oncolo-
gists (n10), plus focus groups and individual interviews with BrCa patients (n20)
from Ontario, Canada. BrCa patients who underwent genomic testing (‘On-
cotypeDx’), were recruited through oncology clinics from two academic hospitals
in the Greater Toronto Area. Medical oncologists were recruited through partici-
pating oncology clinics, professional advertisements and referrals from the re-
search team. Data were analyzed using interpretative qualitative methods, includ-
ing content analysis, qualitative description and constant comparison techniques.
RESULTS: Patients and oncologists valued GEP as an additional decision-support
tool, complementing existing clinical indicators, though perceived utility varied
between patients and oncologists. Patients valued the test highly, suggesting it was
one of the primary determinants of their treatment decision. All patients followed
the course of action their results suggested. Patients with intermediate scores often
used the results to reinforce their pre-existing treatment preferences. Oncologists
were mixed about the test’s utility. Some considered it another tool supporting
their approach to risk assessments; others used it more definitively to resolve their
uncertainty. Oncologists explained the test’s contribution to decision-making but
remained uncertain about patients’ understanding and expectations of the test.
Some raised concerns about the variability of its use and interpretation within their
medical community. CONCLUSIONS: Patients and oncologists valued the test, of-
ten using it as a primary determinant in their treatment decision, despite oncolo-
gists’ concerns about its technical limitations and patients’ limited understanding.
Results identify need for informational decision aids and practice guidelines to
support patient understanding and standardized application of the test.
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OBJECTIVES: Cytotoxic chemotherapy has been the main approaches to cancer
therapy, but frequently poor survival benefit and substantial toxicity is observed.
Over the past decade, cytostatic drugs has been developed and hoped that such
anticancer agents would have low toxicity and prolong survival. In Korea, cytotoxic
therapy is also the standard of cancer treatments, and the National Health Insur-
ance (NHI) program pays 95% of the total medical cost for cancer patients. However,
the cost of cytostatic therapy of Korean traditional medicine is not covered by the
NHI. In spite of such high cost, patients still seek to traditional medicine of cyto-
static therapy. Characteristics of these patients and future research directions are
presented. METHODS: Cytostatic drug which is founded on Korean traditional
medicine is the main anti-cancer agents in our cancer center. Since this is oral
drug, oncology trained medical coordinators offered consultation including eligi-
bility for intake. After consultation eligible patients decide the first visit. We re-
viewed and analyzed telephone consultation logs and first visit medical records to
investigate patient characteristics. RESULTS: A total of 19,815 calls were received,
and about 25% made the first visit. Log showed similar gender, and wide range of
age. Most (67.7%) had one or more metastatic sites. Majority was able to eat and
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move, but some had ascites, pleural effusion, jaundice, dyspnea (3-10%), and used
narcotic (13%). At first visit, as old as age 97 received care (mean age 54.8/14.3;
ranged 1-97), and lung, hepatobiliary, colon, gastric, breast and pancreatic cancer
were comprised of 80% of cancers. Among these about 40-50% had poor perfor-
mance status (ECOG 2-4). CONCLUSIONS: In consideration of the size of the center
and non-insured, offering cytostatic therapy received with remarkable attention by
the patients previously treated with cytotoxic therapy. Further research is needed
to investigate cons and pros of cytostatic therapy.
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OBJECTIVES: In some BCC patients, tumors may progress to locally advanced dis-
ease or become metastatic (aBCC). BCCNS (Gorlin syndrome) is a rare genetic con-
dition associated with life-long occurrence of multiple BCCs. Surgical treatments
may cause disfiguring scars. The patient experience for those with aBCC and BC-
CNS is not well understood. Qualitative research was conducted to develop a PRO
questionnaire for this population. METHODS: Concept elicitation interviews were
conducted in aBCC or BCCNS patients  18 yr and physicians using an interview
guide containing open-ended questions about symptom impact on functioning
and well-being. Results from patient interviews were used to develop draft ques-
tionnaires. Cognitive debriefing interviews were conducted to finalize the
questionnaires. RESULTS: Thirty patients were interviewed [14 aBCC (8 locally
advanced and 6 metastatic; 73% male, mean age 64) and 16 BCCNS (50% male, mean
age 51)]. Patients experience a variety of disease symptoms including pain, swell-
ing, bleeding, and itching. Physical appearance, specifically scarring and disfigure-
ment, affected 73% of patients. 80% of patients made lifestyle changes (avoided
outdoor activities and intimate relationships). Emotional effects, including worry
about when/where the next BCC would appear, were evident in BCCNS patients
(80%). Physicians (n4) noted aBCC patients worry about cancer and the possibility
of more tumors, while BCCNS patients are concerned about tumor recurrence,
multiple surgeries and disfigurement. Based on interview results, separate aBCC
and BCCNS questionnaires were developed. Ten cognitive-debrief interviews were
conducted to evaluate content and clarity of draft questionnaires. The question-
naires were easy to complete and items were relevant. Minor revisions were made.
The final questionnaires include questions about symptoms, appearance, emo-
tions, worry, lifestyle changes, concerns, and treatment satisfaction.
CONCLUSIONS: There are significant and unique impacts to appearance, daily and
emotional functioning, and HRQoL in aBCC and BCCNS patients. An ongoing vali-
dation study will examine psychometric properties of the questionnaires.
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OBJECTIVES: FDA and EMA have created guidelines for PRO label claims. However,
there have been few PRO-based label claims in oncology (Gnanasakthy, et al., 2012)
since the release of the FDA guidelines. The objective of this research was to ex-
plore factors that might predict regulatory success for PROs. We developed a reg-
ulatory success gradient, and used factors based on literature review, expert inter-
views, and the FDA Guidances to predict success. METHODS: Using a case-control
approach, 10 oncology medications with PRO labels came from two sources: 1) a
review of PROs in oncology labels (Gondek et al, 2007), and 2) a proprietary database
(http://www.mapi-prolabels.org/) containing a list of PRO-based labels. Six controls
were oncology medications with the same indication and mechanism of action, but
without PRO data in the label. Regulatory success was defined from none (no PRO in
the label), through minimal, mild, and moderate, to great success (PRO labeling in
the indication section). Independent factors, derived from literature review, expert
interviews, and the PRO Guidances, possibly related to regulatory success included
conceptual fit, study quality, conformity to PRO Guidance (content validity), psy-
chometrics score, and other PRO characteristics, were evaluated. RESULTS: No
medication achieved great PRO labeling success. Only three medications achieved
moderate regulatory success, seven achieved mild, and five achieved minimal suc-
cess. None of the factors identified as potentially related to regulatory success were
significantly correlated with it (Spearman correlations): Other PRO Characteristics
(0.33), Conceptual Fit (0.09), Study Quality (-0.13), Psychometrics (-0.18), and Con-
formity to the PRO Guidance (0-0.02). CONCLUSIONS: Despite widespread use of
PROs in oncology, very few labels actually include PRO-based results, and further-
more, no medications achieved great success and only three moderate success in
labeling. Based on our regulatory success gradient, driving factors leading to regu-
latory success have yet to be identified.
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OBJECTIVES: Lung cancer is one of the most common high incidence and mortality
cancers. Many lung cancer patients (LCPs) receive chemotherapy not only for cu-
rative treatment, but also to palliate symptoms and maintain or even improve their
quality of life (QOL). Though the impact of substances and duration of chemother-
apy on progression-free and overall survival is intensively investigated, there is
currently only little knowledge on patients’ QOL in regard to the number of CT-lines
administered. METHODS: By means of computer-based patient-reported outcome
monitoring LCPs receiving ambulant chemotherapy (adjuvant or palliative) com-
pleted the internationally validated EORTC QLQ-C30, supplemented by two addi-
tional questions concerning taste alterations. Statistical analysis comprised mixed
linear models to calculate change rates over time and differences between chemo-
therapy lines. RESULTS: A total of 175 LCPs (32% female, on average 68 years old (
10.4 SD) and 5 ( 4.5 SD) assessments/patient) participated in repeated QOL-assess-
ment during ambulant chemotherapy administration. Twenty percent of LCPs re-
ceived adjuvant chemotherapy, 73.1% 1st line palliative chemotherapy and 6.9% 2nd
or above line chemotherapy. 70.7% were diagnosed with NSCLC, 21.0 % with SCLC
and 8.3% with other types of lung cancer. Symptom trajectories during adjuvant
chemotherapy did not show a significant change in QOL-scores. LCPs receiving 1st
line palliative chemotherapy experienced improvement concerning sleep distur-
bances (-1.9 points/month, p.009), but deteriorations in regard to appetite loss
and taste alterations (2.8 points/month, p.001, respectively), constipation (1.8
points/month, p.020) and financial impact (1.3 points/month, p.038); 2nd or
above line palliative chemotherapy was associated with stronger symptom burden
than adjuvant or 1st line palliative chemotherapy in most of the EORTC QLQ-C30
domains (e.g. physical, emotional and cognitive functioning, pain and appetite
loss). CONCLUSIONS: Though aggressive, adjuvant treatment did not endanger
patients’ QOL. 1st line palliative chemotherapy proved to be helpful in maintaining
and stabilizing patients’ QOL, since deteriorations have been limited.
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Appropriate utility values for disease states in metastatic castration-resistant pros-
tate cancer (mCRPC) have been contentious in recent economic models submitted
to NICE and other HTA bodies. The validity of mapping algorithms beyond the
range of original data in less symptomatic patients and the evolution of utility once
life-extending treatments have failed, were both considered areas of uncertainty.
OBJECTIVES: To construct and validate a prediction model of preference-adjusted
health status (EQ-5D) for metastatic castration-resistant prostate cancer (mCRPC)
patients using FACT-P (Functional Assessment of Cancer Therapy–Prostate).
METHODS: Observational study conducted in 47 centres across 6 countries (Bel-
gium, France, Germany, Sweden, The Netherlands, UK) collected HRQoL data for
699 patients with confirmed mCRPC and documented disease progression. Utility
values were derived from EQ-5D profiles based on a UK-specific EQ-5D value set (1).
Predictive validity of the 5 FACT-P subscales, patient demographics, co-morbidities
and prior chemotherapy for utility values was tested using ordinary least square
(OLS), median, Gamma and Tobit multivariate regression models. RESULTS: At the
time of assessment, mean age, mean time since diagnosis and failure on androgen-
deprivation therapy were 72.1, 6.6 and 4.1 years respectively; 32% of patients were
treated with chemotherapy, 24% had prior chemotherapy, and 43% were chemo-
therapy naive. At diagnosis, 35.9% of patients had metastases and 84.1% had Glea-
son score 7. Mean FACT-P and EQ-5D utility were 104.0 and 0.67 respectively.
OLS-regression was the best-performing model, explaining 61% of the observed
EQ-5D variation. All FACT-P subscales were significantly predictive. The physical
(coefficient0.023,p0.0001) and functional (0.011,p0.0001) well-being subscales
had the highest explanatory value. Age, co-morbidities and prior chemotherapy
did not add additional explanatory value. CONCLUSIONS: The developed algo-
rithms enable translation of cancer-specific health-related quality of life measures
to preference-adjusted health status in mCRPC-patients. Findings will help to de-
velop health status adjustments in cost-utility analyses used in future HTA’s.
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OBJECTIVES: Malignant ascites (MA) is associated with poor prognosis and limited
palliative therapeutic options. Therefore a change in patients’ health-related qual-
ity of life (HRQoL) is of particular importance to demonstrate added value of a new
treatment to the patient-reported outcomes (PRO). Moreover how fast the change
occurs can be as important as the simple occurrence of a meaningful change in
HRQoL. Following demonstration of superiority on puncture-free survival of catu-
maxomab plus paracentesis vs paracentesis alone, this study aimed to compare
time to deterioration in HRQoL between both treatment groups by using survival
analysis techniques.METHODS: In a randomized, multi-center, phase II/III study in
patients with MA, HRQoL was measured by using the European Organization for
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